Area of research
Psychiatry and Mental health · Physiology
Research interest
Research interests include Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Retinal Imaging and Analysis, and Glaucoma and retinal disorders.
Tau pathology in the retina and its role in neurodegeneration
Retina pathology as a target for biomarkers for Alzheimer's disease: Current status, ophthalmopathological background, challenges, and future directions
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients
Primary retinal tauopathy: A tauopathy with a distinct molecular pattern
Analysis of Psychological Symptoms Following Disclosure of Amyloid–Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline
A retinal tauopathy with a characteristic molecular pattern points to the existence of a “Primary retinal tauopathy”
Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease
Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer’s disease and primary tauopathies
Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review
Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study
New insights into atypical Alzheimer's disease in the era of biomarkers
Retinal imaging in Alzheimer's and neurodegenerative diseases
Retinal changes in Alzheimer's disease— integrated prospects of imaging, functional and molecular advances
Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study
European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain <sup>18</sup>F‐fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus
Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders
Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer’s disease
<scp>EFNS</scp>‐<scp>ENS</scp>/<scp>EAN</scp> Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease
The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean?